ALLR - Latest News
Allarity Therapeutics, Inc. (ALLR), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $13.9M. Beta to the broader market is 0.57.
The article list below shows the most recent ALLR headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent ALLR Headlines
Here's Why Allarity Therapeutics, Inc. (ALLR) Is a Great 'Buy the Bottom' Stock Now
zacks.com - Oct 9, 2026
After losing some value lately, a hammer chart pattern has been formed for Allarity Therapeutics, Inc. (ALLR), indicating that the stock has found su
Critical Review: Evogene (NASDAQ:EVGN) vs. Allarity Therapeutics (NASDAQ:ALLR)
defenseworld.net - Oct 5, 2026
Evogene (NASDAQ: EVGN - Get Free Report) and Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) are both small-cap healthcare companies, but which
Allarity Therapeutics (NASDAQ:ALLR) versus Autolus Therapeutics (NASDAQ:AUTL) Head to Head Analysis
defenseworld.net - Oct 1, 2026
Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) and Autolus Therapeutics (NASDAQ: AUTL - Get Free Report) are both small-cap healthcare compani
Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib's Clinical Development
globenewswire.com - Sep 30, 2026
- Recently awarded patents have solidified Allarity's strategy to leverage DRP to ensure the commercial exclusivity of stenoparib TARPON SPRINGS, Fla.
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research
globenewswire.com - Sep 28, 2026
- Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib - New proteomics and cell line capabilities will broaden
How News Affects ALLR Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ALLR's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked ALLR news questions
- What is the latest ALLR news headline?
- The most recent ALLR headline (Oct 9, 2026) is "Here's Why Allarity Therapeutics, Inc. (ALLR) Is a Great 'Buy the Bottom' Stock Now". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the ALLR news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What ALLR news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual ALLR options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.